{"name":"G2GBio, Inc.","slug":"g2gbio-inc","ticker":"","exchange":"","domain":"","description":"G2GBio, Inc. is a biotechnology company focused on the development of innovative therapies for various diseases. The company has a pipeline of four drugs, all currently in Phase 1 clinical trials, targeting significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GB-5001A","genericName":"GB-5001A","slug":"gb-5001a","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GB-5001A","genericName":"GB-5001A","slug":"gb-5001a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPa2RrZDJKcllvM3BuMS1MS1N1T2pNTDdZRXkwYjZPZk1MSVc2SGhLaUpwbXJGTWFZSTVqUnJ1UFExRUVtdm1iNERzeTF5RHgwdzB4elZ4dFA1dDk3SGtpWFlZcTBCTTZzcXZyWThnMnRHSGswNnY3VlRad2pJNEZXa1RnNnNXWGZuREM4M3dJMTNEUHRsU0U5N0p1WlhIWVYzbFFB?oc=5","date":"2026-03-16","type":"deal","source":"BioWorld News","summary":"G2Gbio secures license deal, ₩20B investment from Samsung Epis - BioWorld News","headline":"G2Gbio secures license deal, ₩20B investment from Samsung Epis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQejVOQWEzZlFvQV9sYlB3ZkpsbC1MdVk2aDBLa2gxOVF2S3RiT0dHUURIOWc3VVUzWGgyNHVOUVFfVW5WYmdiNlYtdVp0M2k3M25Rb2JldERDQTZnVGhiSUZveDlGOGRRdVB4cHhIRWNwXzRtU0YyeHlZWW5YeHB3WjBwWVhBY1pWT09oek1heGhzNnVuMHVibGl6Vy03YUk?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Biopharma IPO activity slows, but 2025 returns are surging - BioWorld News","headline":"Biopharma IPO activity slows, but 2025 returns are surging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVkpOOUNHalZUY1FCOFo2VWRMcUtiazZaeUNreVBpNzU3NzEwVHc5Tlpja2kxWE5lSE10THBoSXBWOUJEVklaTWMwOGxMOTJjbXZsemtZVFpFUzVfTFVJaEFuX0pmRGRsaVNDbTg2VE1WMllLSGNMMnQ4bDE4ZkMweVpwczlUX2ZMdWM2X2VoaUNackh4cE91MUpLMA?oc=5","date":"2025-08-14","type":"pipeline","source":"BioWorld News","summary":"Microsphere injectables biotech G2Gbio debuts with $38M - BioWorld News","headline":"Microsphere injectables biotech G2Gbio debuts with $38M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1QX3FiT2ItWXVqY2ZPekR1UjhQZUM3RnM2bFIyTWtpSDlDeWdiSEJOdGFfUkRxYm5hVml1bWFrMjlYaDdOSG8xaTRGWWdsbmROMGlOWjJaMmV0Uk1nN3NOZ1k4aHhwcUt3T0V3UklB0gFyQVVfeXFMTmhvOU14MVByX0ZpV1hMcjJXTVFBTEtRM0JUaGI3cjAyR2VZUWhKVHNiaXlaeXZTMVA5Si14bGEwMVNsQlJWcm9KRjhVSWhfblowazNXV2Z6SnE5LWxEdWtsaW1fT3EtYkZrMEZYZEdBQzNR?oc=5","date":"2025-07-31","type":"pipeline","source":"koreabiomed.com","summary":"G2G Bio to expand long-acting injectable platform with IPO - koreabiomed.com","headline":"G2G Bio to expand long-acting injectable platform with IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQemx4Ul9LbHR5WHgzaThwcDlDRktKVFJySGROZUpUT01XNC1QOFo3WFVXY2ZBYXBYZFg1azJUX2ZhaVpObWUtRGRDdVhvVEc5RDhQZ2Rmdi1wY08tbDFZbkpiR2hJNFU1eG5hbDZ6RERFcE5MV21pcEx0a2dKS1o3atIBlAFBVV95cUxQanVjdlUtUHdpWFlhUE1pZmdfMDdnX1VOenF5UEFVb2dlaHktNUZXT1A2bGUxcnZZcUdPRnFPQlVUS1cxQWgwQWJlY0U1NVNEQTZWOUVyeVdqM0JVRkZuSlZ1RFpHZWhHTDBoVHhQZmxUcEdMeHpFdGFXcVo1NXA2QjFQd2JPMEV1VjJBME1lZHFVQlZq?oc=5","date":"2025-07-03","type":"deal","source":"Chosunbiz","summary":"Big Pharma partnerships boost biotech IPO expectations in South Korea's KOSDAQ - CHOSUNBIZ - Chosunbiz","headline":"Big Pharma partnerships boost biotech IPO expectations in South Korea's KOSDAQ - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVlo0UlJ3YmZfN1Foa3J1end3NHMyb0hXekVqQ0h3X2l6SVFwcnZlQkdGNXhqZzFGZWMwTUxxZkU5QTBZcUNGNDRheUIxWWVkMkZySm9qMXU0bnVadmVaMGRHdEF6RjU3SDJWM0VqNWQyaUJlUkNWY3puLUNIb1pSbk1HZEtBZFNkdmlkN1EzTmM4bjFkNkFpRHc0NjlZRnpWMDE1VGhkUzg?oc=5","date":"2025-06-17","type":"deal","source":"BioWorld News","summary":"Korea biotech roundup: four financings, six R&D deals mid-June - BioWorld News","headline":"Korea biotech roundup: four financings, six R&D deals mid-June","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE0wQmxudXEwWmtiVk95emVDbHpCMFVGd0MwNHR1TFVaSW1FVEJ4UnJFLTFzN2hKams0QkxlVnJGWVZzZVRoSHhCYTV5MGxQOHJZdFhrMWstZlIyd3dKU3RkaVVCOWJvRU9UVi1iQmtR?oc=5","date":"2023-10-18","type":"trial","source":"KED Global","summary":"Humedix gets gov't OK for trials of dementia candidate drug - KED Global","headline":"Humedix gets gov't OK for trials of dementia candidate drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE43eXlyNWxSTkdram9LWWt2X09tYUY5cDYtSk9JM281dEtXSFNPS2ViVnhkaV9pOC0teHZlV1hSaWZQbFAwemx3VHdEcGFKRHQ5OXRMeEdQUQ?oc=5","date":"2021-03-08","type":"pipeline","source":"바이오스펙테이터","summary":"G2GBIO “Fills the Gap” between “Technological Barrier and Market Needs” for Sustained-Release Preparations - 바이오스펙테이터","headline":"G2GBIO “Fills the Gap” between “Technological Barrier and Market Needs” for Sustained-Release Preparations - 바이오스펙테이터","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQZnUzZ04ybUJGWkJySklFN2IyLVBVQXlmYVFwZWlTb0pDMHJUMFNjWTlDU3ZaU3k3YUtyNVp5Ti1tNUE3MlJvZUx3SmlXMjZRYWhTemdlNFdUbW9WV0Ftay1qWWd5TmhwU2dEcUxuWG5IRUd4SDJvNy1FYVJfYS1hTmlvUnR0WnRoQVM0RXNNMDVOOXNDaEpZZGdBa0xLdWlnd1hvOENR0gHaAUFVX3lxTE1oNE4yZ2NQTEYxcGNGMWlITnQ2Vi1LOVM1dUNCWGx0aXdMTU9RaGVfUnlleXNtZlBLWlk0TmZjUmxUUFdRbmg1djFSclFJS1RXVkZNblFULXNseTEyNC1naXVEc2tmWHRidlFnczU3R1hBZ29qUllVQk9UeXdmU2JVRng4cXBFVUU5OXplVXlJSUJkc200aHhqME5LaDdlbHVDYjZIMWNVZzl2WDlRVncxbUY4VU1oc2VlVG0xMjhqMUd2cFlTdW1VWjNNa3VXdzZpQUZUWEp6alNR?oc=5","date":"2020-04-20","type":"pipeline","source":"Cedarville University","summary":"South Korea Residents Benefiting from Cedarville Pharmacy Graduate - Cedarville University","headline":"South Korea Residents Benefiting from Cedarville Pharmacy Graduate","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}